INBRX-106 Phase 1/2 Trial
An Open-Label, Multicenter, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors.
ClinicalTrials.gov
Key Eligibility Criteria:
+ Aged ≥18 years
+ Any PD-L1 TPS (including 0%)
+ Previously untreated, histologically confirmed NSCLC